Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03591146 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Dose-escalation Study to Evaluate Safety, PK and Efficacy of TLC590 for Postsurgical Pain Management
A Phase 1 study, sponsored by Taiwan Liposome Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT03591146: Completed Phase 1 study, sponsored by Taiwan Liposome Company.
NCT03591146 is a Phase 1 study that has completed, run by Taiwan Liposome Company. The registered enrollment target is 65 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03591146, a Phase 1 study, has completed, sponsored by Taiwan Liposome Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
Phase I/II, randomized, double-blind, comparator-controlled, dose-escalation study to assess the safety, PK, and efficacy of single postsurgical application of TLC590 compared with Naropin®
Primary Outcome
Event of serious adverse event (SAE) and treatment-related severe adverse event (TRAE)
Interventions
- DRUG TLC590
- DRUG Naropin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2018-07-31 |
| Est. Completion | 2019-01-14 |
| Phase | Phase 1 |
What the finished NCT03591146 record still lists
NCT03591146 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which TLC590 is the first listed.
NCT03591146 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03591146 about?
NCT03591146 is a clinical study titled "Phase I/II Dose-escalation Study to Evaluate Safety, PK and Efficacy of TLC590 for Postsurgical Pain Management". Phase I/II, randomized, double-blind, comparator-controlled, dose-escalation study to assess the safety, PK, and efficacy of single postsurgical application of TLC590 compared with Naropin®
What is the current status of trial NCT03591146?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2018-07-31. Estimated completion is 2019-01-14.
What interventions are being tested in trial NCT03591146?
The interventions under investigation include: TLC590 (DRUG), Naropin (DRUG).
Who is sponsoring clinical trial NCT03591146?
This trial is sponsored by Taiwan Liposome Company, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03591146's enrollment target sits among peer trials
65 798th of 2000 higher than 1,193 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI